Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
carfilzomib (kyprolis) (1 trial)
irinotecan (Camptosar) (1 trial)
bevacizumab (avastin) (1 trial)
carboplatin (paraplatin) (1 trial)
everolimus (zortress) (1 trial)
pemetrexed (alimta) (1 trial)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Hypersensitivity (Phase 2)
Lung Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Trials (2 total)
Trial APIs (6 total)